Tenderwize
Back to tender search

Open-house drug rebate agreements Berlin

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 189 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Berlin

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

30 / 100

Risk factors

Open-House model may be superseded by regular discount contracts, leading to automatic termination of existing agreemen...

No guarantee of sales volume; contracts are non-exclusive and volume depends on prescribing behavior.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 3 lots
  • Duration until Apr 2027
  • Conclusion of non-exclusive discount agreements for oncology medications under §130a Abs. 8c SGB V
  • Medications: Bevacizumab, Rituximab, Trastuzumab (parenteral preparations from finished drugs)
Show full summary

Open-House procedure for non-exclusive discount agreements for oncology drugs (Bevacizumab, Rituximab, Trastuzumab) in Berlin. Eligible pharmaceutical companies can join at any time until 21.02.2027. Contracts run from 01.05.2026 to 30.04.2027. No estimated value provided. No competition-based award; all eligible participants are accepted.

Risks

Open-House model may be superseded by regular discount contracts, leading to automatic termination of existing agreemen...

No guarantee of sales volume; contracts are non-exclusive and volume depends on prescribing behavior.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Current commercial register excerpt (not older than 2 years) or power of attorney

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible

Administrative

  • Suitability proof via a signed self-declaration of reliability

Requirements may be incomplete.

Buyer

Location

Potsdam, DEU

Website

www.aok.de

Identifier

DE275390265

Activity

Health

Lots (3)

LOT-0001

Bevacizumab (ATC: L01FG01)

Non-exclusive discount agreement for Bevacizumab parenteral preparations for oncology use in Berlin. Open-House model, all eligible pharmaceutical companies can join.

SuppliesEU fundedElectronic submission

Location

Germany

Duration

Apr 2026 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 21, 2027

LOT-0002

Rituximab (ATC: L01FA01)

Non-exclusive discount agreement for Rituximab parenteral preparations for oncology use in Berlin. Open-House model, all eligible pharmaceutical companies can join.

SuppliesEU fundedElectronic submission

Location

Germany

Duration

Apr 2026 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 21, 2027

LOT-0003

Trastuzumab (ATC: L01FD01)

Non-exclusive discount agreement for Trastuzumab parenteral preparations for oncology use in Berlin. Open-House model, all eligible pharmaceutical companies can join.

SuppliesEU fundedElectronic submission

Location

Germany

Duration

Apr 2026 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 21, 2027

Procurement Details

Publication date
11 Feb 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
103459-2026

Documents (2)

Similar tenders